Drug Profile
Sitimagene ceradenovec
Alternative Names: Cerepro; EG009Latest Information Update: 16 Mar 2011
Price :
$50
*
At a glance
- Originator Ark Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference; Thymidine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Glioma
Highest Development Phases
- Discontinued Glioma
Most Recent Events
- 05 May 2010 Sitimagene ceradenovec is available for licensing worldwide (http://www.arktherapeutics.com)
- 05 Jan 2010 Ark Therapeutics files formal request with the EMEA for re-examination of MAA for sitimagene ceradenovec in operable malignant Glioma
- 18 Dec 2009 CHMP adopts negative opinion of sitimagene ceradenovec in operable malignant Glioma in Europe